BIIB vs TRU · P/E 21, rev $9.89B vs P/E 19, rev $4.58B
Biogen Inc (BIIB) versus TransUnion (TRU) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
TransUnion (TRU) is a financial data & stock exchanges company listed on NYSE.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported TRU revenue for 2025-12-31 was $4.58B. Net income was $455.4M. Revenue was up 9.4% from 2024-12-31 to 2025-12-31. TRU currently screens at market cap $13.41B and trailing P/E 19.3.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. TRU currently screens at market cap $13.41B and trailing P/E 19.3.
Not investment advice. Open the BIIB and TRU stock pages for the full models.
Not investment advice.